Abstract
Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) was first notified in Wuhan, China, in December 2019, and has rapidly spread worldwide, due to its high transmission rate. It has been identified as the causative agent of the now termed coronavirus disease (COVID-19), which can range from mild condition to potentially fatal respiratory distress syndrome
Highlights
Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) was first notified in Wuhan, China, in December 2019, and has rapidly spread worldwide, due to its high transmission rate. It has been identified as the causative agent of the termed coronavirus disease (COVID-19), which can range from mild condition to potentially fatal respiratory distress syndrome [1]
The therapeutic potential of certain drugs used for other diseases has led to their offlabel use for COVID-19, such as antiretroviral drugs, corticosteroids, biological treatments, antiparasitics and antibiotics [2]
Cytochrome p450 enzymes are affected by protease inhibitors which could lead to neurotoxicity by altering plasma concentrations of multiple psychotropic drugs
Summary
Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) was first notified in Wuhan, China, in December 2019, and has rapidly spread worldwide, due to its high transmission rate. It has been identified as the causative agent of the termed coronavirus disease (COVID-19), which can range from mild condition to potentially fatal respiratory distress syndrome [1]. The therapeutic potential of certain drugs used for other diseases has led to their offlabel use for COVID-19, such as antiretroviral drugs (lopinavir-ritonavir, darunavir, remdesivir), corticosteroids, biological treatments (tocilizumab), antiparasitics (hydroxychloroquine and nitazoxanide) and antibiotics (azithromycin) [2].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
